Mari Rhodehamel Yin

Executive Officer, Director at Sentrimed.

Mullica Hill, NJ
Sentrimed

Raised on Sentrimed filings

$250K

of $1M offered across 1 Form D filing

Form D filings: 1
Teammates: 7
Last filing: May 13, 2026

Company

Biotech · Mullica Hill, NJ

Oral podoplanin inhibitor for head and neck cancer

Oral podoplanin inhibitor for head and neck cancer

Investors: 1
Founded: 2023
Still open: $750K

Investors: 1
Sector: Biotech
Founded: 2023
HQ: Mullica Hill, NJ

Sentrimed filings

Sentrimed Form D filings
Filed	Security	Sold of offered	Filing
May 13, 2026	Security to be acquired	$250K/ $1M	Form D

Security to be acquiredFiled May 13, 2026Form D
$250K/ $1M

Works with

Also named on Sentrimed filings

William RagatzPresidnet, Form D signerForm D signer Tabbetha DobbinsDirector Arye RosenExecutive Officer Bradley GalerDirector Christopher LeonardExecutive Officer Gary GoldbergExecutive Officer Jack GoldbergExecutive Officer, Director